Clinical adenoviral p53 gene therapy has been shown by us and others to inhibit tumor growth of ovarian cancer with endogenous mutant p53. This study was designed to test the cooperative antitumor effect of standard combination chemotherapy using paclitaxel and carboplatin together with adenoviral p53 gene transfer in the presence of wild-type and mutant p53. Seven ovarian cancer cell lines with mutant p53 and seven ovarian cancer cell lines with wild-type p53 were tested. An E1-deleted adenovirus type 5 expressing p53 (ACNp53) was used for p53 gene transfer. p53 gene transfer at 50% transduction efficiency significantly reduced IC 50 of carboplatin chemotherapy up to 49-fold, of paclitaxel chemotherapy up to six-fold, and of paclitaxel/carboplatin chemotherapy up to 19-fold in the wild-type p53 cell line OV-MZ-5. Synergism between ACNp53 and chemotherapy calculated by median-effect analysis was found at low drug concentrations in all cell lines independent of the p53 mutational status. In conclusion, adenoviral p53 gene transfer significantly increased the sensitivity of ovarian tumor cells to paclitaxel, to carboplatin and/or to the combination of both.
O varian cancer has a high mortality rate and is the fourth leading cause of cancer-related deaths among women in Western countries. 1, 2 The standard treatment of ovarian cancer is based on surgery followed by a combination chemotherapy including a platinum-derived agent such as carboplatin and paclitaxel with a response rate of approximately 80%. 3, 4 Chemoresistance, however, is an important factor causing relapse or progress of the disease in the majority of the cases. Targeted therapies such as p53 gene therapy strategies are thought to increase the capability to induce tumor cell death effectively. Clinical p53 gene therapy studies have demonstrated a possible benefit for patients with p53 mutant ovarian cancer. 5, 6 Alterations of the p53 gene are found in 50-70% of ovarian cancer 7 contributing to impaired control of cell cycle, DNA repair, and apoptosis. p53 gene mutations occur even more frequently in recurrent ovarian cancer and may affect response to chemotherapy. 8 Gene transfer of a wild-type p53 gene is intended to reverse the loss of normal p53 function and has been demonstrated to reduce proliferation of tumor cells alone or in combination with chemotherapy in vitro and in vivo among different types of tumors, such as breast, 9 ,10 head and neck, 9 ,10 prostate, 9,10 pancreas, 11 lung, 12 as well as ovarian cancer. 9, 10, 13, 14 At least three major issues remain unclear when this therapeutic strategy is applied to ovarian cancer: the efficiency of the adenoviral transduction in ovarian cancer cells, the effect of adenoviral p53 on tumor cells with endogenous wild-type p53, the efficacy of the combination of current standard paclitaxel/carboplatin chemotherapy with adenoviral p53 gene transfer, systematically analyzed with regard to the mutational status. In this study, an E1-deleted adenovirus type 5 expressing p53 (ACNp53) was transferred into 14 ovarian cancer cell lines with different p53 mutation status to determine its effect in combination with paclitaxel/carboplatin chemotherapy. Synergism was detected for certain combinations of gene and chemotherapy using dose-effect calculations.
Materials and methods

Cell culture and p53 status
A total of 13 permanent human ovarian cancer cell lines established in our laboratory, OV-CA-2774 available from the American type Culture Collection (ATCC) and HEK293 cells, available from the German Collection of Microorganisms and Cell Cultures (DSMZ), were used in this study. p53 status was determined by sequencing of the entire cDNA and confirmed by sequencing of the genomic DNA. Mutation status of our established cell lines were: OV-MZ-1a: sequence mutation of CTT to CT at codon 194, OV-MZ-2a: TAT to TGT at codon 220, OV-MZ-8: GCC to GGC at codon 276 and a deletion in codon 273, OV-MZ-32: 13 base pair deletion from codon 314, OV-MZ-35: TCC to TTC at codon 127 and CGA to CGG at codon 213, OV-UL-2: TAT to TGT at codon 205, OV-MZ-5, OV-MZ-6, OV-MZ-16, OV-MZ-22, OV-MZ-36 and OV-MZ-38: all wild-type p53. Cells were grown as attached monolayers in Dulbecco's modified Eagle's medium (DMEM, Invitrogen) containing 10% fetal calf serum (FCS), 1% HEPES buffer, 1% penicillin/streptomycin/glutamine (Invitrogen) and 1% arginine/asparagine under humidified conditions at 371C and 5% CO 2 .
Viral vectors
An E1-deleted adenovirus type 5 expressing wild-type p53 under the control of a CMV-enhancer/promoter (ACNp53) was used for p53 gene transfer. 15 The same vector expressing b-galactosidase (AdGal) was used to control for gene transfer efficiency. For propagation of AdGal and ACNp53, HEK293 cells were grown in DMEM 10% FCS to 90% confluency on 150 mm dishes and infected with AdGal or ACNp53. When the cytopathic effect became visible, the medium was collected and centrifuged, the supernatant was stored in aliquots at À801C.
Viral titers
Viral titers were determined by photometry 16 and by the cytopathic effect assay (CPE-assay). For the CPE assay, 2 Â 10 6 cells/well of 293 cells of a low passage number (to a maximum number of 8) were seeded in six-well plates overnight. Cells were infected for 1 hour with different dilutions of ACNp53 (dilutions of 1:10, 1:10 ) or AdGal (dilutions of 1:2, 1:5, 1:25, 1:125, 1:625, and 1:3125) in FCS-free DMEM. After adenoviral infection, the medium was replaced by fresh DMEM 10% FCS and cultured for another 48 hours. Plates were daily monitored for cytopathic effect and the dilution that causes cytolysis was used to calculate the adenoviral titer.
Transduction efficiency
Adenoviral transduction efficiency (ATE) was determined by X-Gal-staining (5-bromo-4-chloro-3-indolyl-b-D-galactopyranoside) after applying AdGal as described before. 17 Only cell lines of more than 60% transduction at MOI 400 were selected for further experiments. Additionally, adenoviral transduction efficiency (ATE) of all 14 cell lines was controlled in 96-well plates simultaneously to p53 gene transfer experiments. These data were analyzed by a software designed to calculate dose-effect relations as described below (see Data analysis). This allowed the calculation of the infection dose in multiplicity of infection (MOI) that resulted in 50% ATE as expressed by ED 50 (effective dose at 50% transduced cells).
Drugs
To apply conditions similar to those in vivo, we used a concentration of 20 mg/ml carboplatin equivalent to the 2-hour plasma concentration of AUC 5 (area under the curve) and 5 mg/ml paclitaxel (maximum plasma concentration of a 3-hour infusion of 175 mg/m 2 ) 18 as 100% therapeutic dose (TD). Combination chemotherapy of carboplatin/paclitaxel was applied with 100%TD of each agent, 20 mg/ml plus 5 mg/ml, respectively. TDs of 200%, 100%, 50%, 25%, 12.5%, and 6.25% were tested for all cell lines with or without ACNp53. All drugs were diluted in the culture medium DMEM/10% FCS.
Adenovirus-mediated gene transfer and drug exposure
For adenovirus-mediated gene transfer, 4 x 10 3 cells/well were seeded in 96-well plates and cultured overnight. On the next day, medium was changed to fresh FCS-free DMEM containing the adenoviral p53 (ACNp53) or AdGal at different titers. After cells were infected for 2 hours, medium was changed for fresh DMEM/10% FCS containing either carboplatin, paclitaxel or carboplatin plus paclitaxel combined. Cells were incubated for 72 hours before MTT assay.
MTT assay
Cellular viability was determined by the semiautomatic 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide (MTT)-assay as described elsewhere. 19 After incubation for 72 hours as described above, 20 ml sterile filtered MTT in PBS (5 mg/ml) was added to each well. Following 3 hours incubation at 371C and 5% CO 2 , the supernatant of all wells containing unconverted MTT was replaced by 100 ml DMSO. After 5 minutes of shaking, the crystal formazan was dissolved in DMSO and read at 540 nm by an ELISA-microplate-reader.
Data analysis
All of the results represent the means of eight identically treated wells. These data were analyzed by using a doseeffect calculation software (Calcusyn, Biosoft, Oxford, UK) based on the principles of the median-effect analysis, 20 using a refinement of the classical isobologram method and Microsoft Excel. This allowed the calculation of the inhibition concentration of the drug at 50% decrease of cell viability (IC 50 ). The same method was used to calculate the IC 50 at 50% ATE. Additionally, the quantitative interaction of different therapeutic agents was expressed by a combination index (CI). 20 CI values of less or greater than 1 indicated synergism or antagonism, respectively. CI values equal to 1 indicated additive effect. Resistance or responsiveness to treatment was defined as an IC 50 of more or less than 100%TD. To analyze significance (Po.05), a two-sided Student's t-test was used to compare decrease of cellular viability after chemotherapy and chemotherapy plus virus.
Apoptosis detection by Annexin-FITC affinity assay
A total of 2.5 Â 10 5 cells were seeded in 6-well dishes overnight and then infected with ACNp53 or AdGal for 2 hours in FCS-free DMEM. Supernatant was replaced by fresh DMEM 10% FCS containing either the therapeutic agents or no drugs and incubated for 72 hours as described above (MTT Assay). After 72 hours the cells were carefully removed from the bottom with 500 ml of 0.05%/0.02% Trypsin/EDTA in PBS and washed twice with 1 ml cold PBS. Annexin-V-Fluos Staining Kit (Boehringer Mannheim) was used with 20 ml of propidium-iodide and 10 ml of Annexin-V and analyzed by fluorescence-activated cell scanning (FACS-Calibur, Becton Dickinson).
Results
Adenoviral gene transfer of AdGal and ACNp53 into ovarian cancer cells
Transduction efficiencies significantly differed among the tested ovarian cancer cell lines. Table 1 summarizes the MOI needed to achieve an effective transduction efficiency (ATE) of 50% (ED 50 ) with AdGal reporter virus. All 14 ovarian cancer cell lines were treated with different titers of ACNp53 or AdGal and titers necessary for 50% decrease of cellular viability (IC 50 ) are summarized in Table 2 . In all cell lines of mutant p53 and in four of seven cell lines with wild-type p53 (OV-MZ-5, OV-MZ-16, OV-MZ-22, OV-MZ-36) the titer of ACNp53 to achieve 50% viability was lower than with reporter virus AdGal. p53-mediated decrease in cell survival was related to transduction efficiency in OV-UL-2, OV-MZ-2a, OV-MZ-32 and OV-MZ-35 cells (Tables 1 and 2) as determined with AdGal, but not in OV-MZ-5 and OV-MZ-8 cells, which showed poor adenoviral transduction efficiency (Table 1) but responded well to ACNp53 in contrast to AdGal (Table 2) . However, OV-MZ-6 and OV-MZ-38 cells showed high transduction efficiency but poor response to ACNp53.
Adenoviral p53 gene transfer increased the sensitivity of ovarian cancer cells to paclitaxel and/or carboplatin
The 14 ovarian cancer cell lines were treated with ACNp53 at different MOI, AdGal was applied in parallel as a control. After incubation with ACNp53 or AdGal, cells were treated with the indicated chemotherapeutic drugs at different concentrations and the corresponding IC 50 values were calculated at a MOI of 50% adenoviral transduction ( Table 3 (Table 3) . Reduction 
Synergism of ACNp53 and low drug concentrations of chemotherapy
CI values for the interaction of paclitaxel with carboplatin and for the interaction of ACNp53 with paclitaxel and carboplatin at MOI 50 are listed in Table 4 . Synergism (CIo1) was observed for the interaction of ACNp53 with 6.25%TD paclitaxel/carboplatin (0.31 mg/ml paclitaxel/ 1.25 mg/ml carboplatin) in all cell lines tested. Higher doses of chemotherapeutics decreased the cooperative effects of ACNp53 and chemotherapeutics in most cell lines and lead to even antagonistic effects. At 0.63 mg/ml paclitaxel and 2.5 mg/ml carboplatin, synergism was found in seven out of eight cell lines, an antagonistic effect was observed in OV-MZ-8 cells. At 1.25 mg/ml paclitaxel and 5 mg/ml carboplatin, synergism was found in three cell lines with five cell lines showing an antogonistic effect. (Table 5 ). In OV-UL-2 cells, mutant-type p53, poor response to single carboplatin and/or paclitaxel at 100%TD was observed ( Table 5 ). Addition of AdGal at MOI 25 did not increase the level of apoptotic cells, whereas addition of ACNp53 at MOI 25 strongly increased the number of apoptotic cells (Table 5) . Combination of ACNp53 with carboplatin was significantly more effective in the induction of apoptosis when compared to treatment of ACNp53, carboplatin alone or in combination with reporter virus AdGal in OV-MZ-5 cells, wild-type p53 and OV-UL-2, OV-MZ-2a, and OV-MZ-35 cells, mutant-type p53 (Table 5) . Most apoptotic cells were observed with ACNp53/paclitaxel/carboplatin compared to any other combination in four out of eight cell lines (OV-MZ-1a, OV-MZ-2a, and OV-MZ-8, mutant-type p53, and OV-MZ-22, wild-type p53; Table 5 ).
Discussion
Adenoviral p53 gene transfer has been shown to inhibit tumor growth in a wide range of human tumors including ovarian cancer. 15, 21 For ovarian cancer cells, it has been demonstrated that tumor regression could only be observed in human ovarian cancer xenografts lacking functional p53 but not in those with wt p53 status. 22 Further reports described a significant increase of apoptosis when p53 was reintroduced into mt p53-containing but not wt p53-containing ovarian cancer cells. 23 Jin et al 24 reported on two wt p53-containing ovarian cancer cell lines that were more resistant than mt p53 cell lines to apoptosis and growth suppression as induced by exogenous wt p53. In contrast, investigations by Wolf et al 14 assumed that adenovirus-mediated growth inhibition of ovarian cancer cells may be independent of endogenous p53 status when virus doses were used to transduce at least 50% of the cell population. We observed an increase of apoptotic cells in the wt p53 cell line OV-MZ-5 and the chemoresistant mt p53 cell line OV-UL-2 after p53-gene transfer. Decrease of cell viability after wt p53 gene transfer seemed to depend rather on viral vector dose and adenoviral transduction efficiency than on the p53 mutational status of the cancer cells. Recent reports demonstrated that p53 missense mutants markedly reduced DNA binding of wild-type p53 Previous reports have demonstrated that the combination of adenoviral p53 and cisplatin was cooperative in ovarian, breast, lung, pancreatic, prostate, head and neck cancer cells expressing mutant p53. [10] [11] [12] [26] [27] [28] Furthermore adenoviral p53 might enhance the effect of taxanes in lung and ovarian cancer. 9, 10, 12, 29 Although it appears that p53 is not involved in paclitaxel-dependent apoptosis, 30 it may enhance adenoviral transduction efficiency. 9 In our study, testing a representative number of 14 ovarian cancer cell lines, we observed that adenoviral p53 gene therapy improved paclitaxel and/or carboplatin chemotherapy in cell lines with mutant p53 as well as with wt p53. The cooperative effect using the combination of ACNp53 and paclitaxel/carboplatin to reduce cell viability was mainly evident at low therapeutic doses of the chemotherapeutic drugs. When we applied the computer-based dose-effect analysis, synergism occurred when low drug concentrations of 6.25-12.5%TD were combined with titers of ACNp53, MOI 50 or higher. Furthermore, we realized a significant decrease of cellular viability in ovarian cancer cells independent of their p53 status at MOI 25 as well as strong decrease of the corresponding IC 50 at 50% adenoviral transduction. Currently, it remains debatable if such infection rates are within reach in vivo.
In clinical trials, adenoviral p53 is applied by direct injection, i.p., or systemic infusion. It is well tolerated and no maximal tolerated dose could be detected even for repeated doses of 10 11 plaque-forming units (PFU) 27, [31] [32] [33] or 7.5 Â 10 13 particles. 5, 6 The main problem remains the low infection rate of tumor cells due to low transduction efficiency by adenovirus type 5 and neutralization by antiadenoviral antibodies. 5 This might be the reason that higher infection rate, transgene expression, mean apoptotic index, and clinical benefit are reported for repeated doses 5, 6, [32] [33] [34] and in some studies for direct intratumoral injections, where immune response is less effective, 27, [31] [32] [33] [34] rather than for the systemic i.v.-or i.p.-route of administration. 5, 6 However, tumor eradication by adenoviral p53 in combination with chemotherapy may not always depend on transduction efficiency as seen in wt p53 cell line OV-MZ-5. Furthermore, a bystander effect due to angiogenesis 35 only observed in vivo may reduce the high virus dose necessary for tumor eradication and synergism calculated in vitro. Another problem is that the amount of tumor cells infected in vivo is unknown even if transgene expression of adenoviral p53 could be detected in tumor tissue after adenoviral p53 application. 5, 6, 33 A quantitative analysis of adenoviral transduction has been found difficult since the total amount of tumor cells could not be determined. 5 For this purpose, vectors of higher transduction efficiency such as conditionally replicative adenoviruses and drugs enhancing viral transduction efficiency are needed. 36, 37 Infectivity-enhanced vectors that bypass the CAR gateway using the integrin entry instead 38 in combination with a radiolabeled noninvasive For the clinical situation, according to our results, ACNp53 could help to reduce the therapeutic serum concentration of paclitaxel/carboplatin, thereby possibly allowing to extend the total number of chemotherapeutic courses with a reduced risk of adverse events. However, it must be considered that reduction in the number of chemotherapy courses or total drug concentration of paclitaxel and/or carboplatin could diminish their total anticancer activity. In our experiments, we used 5 mg/ml of paclitaxel as 100%TD, mimicking the clinical maximum plasma concentration of a 3-hour infusion of 175 mg/m 2 paclitaxel. According to other reports, the individual maximum plasma concentration of this regimen can reach only 2 mg/ml and an infusion of 175 mg/m 2 paclitaxel applied over 24 hours only a maximum of 0.195-0.420 mg/ ml with similar overall tumor response in these patients. 39 In these scenarios as well as during drug metabolism, leading to even lower drug concentrations, combination therapy with ACNp53 and paclitaxel/carboplatin chemotherapy is highly synergistic.
In conclusion, adenoviral p53 gene transfer in combination with the standard carboplatin/paclitaxel chemotherapy is a promising strategy that can effectively eradicate ovarian cancer cells with and without p53 mutation. We, however, advocate for a further evaluation of in vitro testing for sensitivity of the individual tumor cells to be treated.
